Experts Issue GLP-1 Guidance for NET Care

On 15 August 2026 the journal Cancer published a formal expert consensus statement on giving incretin-based therapies, the class that includes GLP-1 receptor agonists such as semaglutide and dual GIP/GLP-1 agonists such as tirzepatide, to patients who have a neuroendocrine neoplasm. The twelve-author panel, led by Udhayvir Grewal of Emory's Winship Cancer Institute and Thorvardur Halfdanarson of the Mayo Clinic, also drew clinicians from Dana-Farber Cancer Institute, Moffitt Cancer Center, the University of Iowa, and neuroendocrine-tumor centers in Canada, the Netherlands and Sweden^[1]. The statement recommends a framework for individualized decisions, not a blanket rule for or against these drugs^[1].

Neuroendocrine neoplasms are an uncommon and biologically varied group of tumors that arise from hormone-producing cells in the gut, pancreas, lungs and elsewhere. Anyone who has one is already under specialist oncology care, and the diabetes or obesity medicine question sits alongside that care rather than replacing it. This article summarizes what the panel actually wrote. It is not medical advice and is not a substitute for a conversation with your treating team.

The statement covers the whole incretin class the panel's patients were being considered for, not one brand. That spans single-target GLP-1 receptor agonists like semaglutide and dual GIP/GLP-1 agonists like tirzepatide. Regulatory status for either drug differs by country, and that detail sits on the United States and United Kingdom regulation pages.

What the panel actually recommends

The consensus statement calls for individualized risk assessment, shared decision-making between patient and clinician, and multi-disciplinary collaboration, weighing an oncologic risk the authors describe as potential but unquantified against cardiometabolic benefits they call substantial^[1]. Until prospective, NEN-specific trial data exist, the panel writes that careful patient selection, dose optimization by the prescribing clinician, and close clinical and radiologic surveillance are what should guide use of incretin mimetics in this population^[1]. That is guidance for oncologists and endocrinologists managing a specific patient, not a script for self-directed use.

Why neuroendocrine tumors raise the question at all

The concern has a biological basis. Preclinical work cited in the statement shows that activating the GLP-1 receptor can promote tumor growth in select receptor-expressing models^[1]. But that signal is not uniform across the disease. Receptor expression varies widely from one neuroendocrine-neoplasm subtype to another, and the panel notes it is often absent altogether in common tumors such as ileal neuroendocrine tumors^[1]. A finding in a receptor-expressing cell line is not evidence that every neuroendocrine tumor responds the same way to the same drug.

What the human data shows, and what it does not

Population-level and retrospective clinical data reviewed by the panel have not shown a consistent increase in oncologic risk in people on incretin therapies, though the authors are explicit that this evidence is limited by the usual methodological constraints of retrospective and registry data: confounding, short follow-up, and imprecise exposure and outcome capture^[1].

A separate, larger dataset points in a similar direction on an adjacent question. A systematic review and meta-analysis in Annals of Internal Medicine pooled 48 randomized trials and 94,245 participants and found that GLP-1 receptor agonists probably have little or no effect on thyroid cancer risk, at moderate certainty of evidence^[4]. Read that alongside its own limits: the trials were not designed to capture cancer outcomes, follow-up was short, and thyroid cancer as a whole is not the same category as a neuroendocrine neoplasm^[4]. Reassurance on one endpoint does not transfer automatically to a different, rarer one.

What this is not

It is not a labelled contraindication for most neuroendocrine neoplasms. The US prescribing information for Mounjaro carries a boxed warning that tirzepatide causes thyroid C-cell tumors in rats, and states it is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined^[2]. The contraindication that follows from that warning is narrow: a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2^[2]. Pancreatic, small-intestinal and other neuroendocrine neoplasms are not named on that label. In the EU, the EMA's authorization of Mounjaro for type-2 diabetes and weight management carries a post-authorization database linkage study specifically to evaluate medullary thyroid carcinoma risk, which is the same narrow question held open a different way^[3].

It is also not a green light. The panel's own language, potential but unquantified oncologic risk, is a call for caution and monitoring, not a declaration that incretin mimetics are safe across every neuroendocrine-neoplasm subtype. And it is not a document written for patients to apply to themselves. It is a framework for the oncologist, endocrinologist and patient to work through together, case by case.

Why this matters now

Incretin mimetics are being prescribed to a growing share of adults with diabetes, obesity and cardiometabolic disease, the same population in which neuroendocrine neoplasms are sometimes diagnosed. Until this statement, oncologists managing a patient with both a neuroendocrine neoplasm and a cardiometabolic indication for a drug like semaglutide or tirzepatide had no formal, specialty-society-adjacent framework to reference. This is the first attempt at one^[1]. It follows an August 2026 European Journal of Endocrinology review that reached a similar conclusion from the epidemiology side: caution and monitoring where a contraindication does not exist, rather than either alarm or reassurance.

Nothing here changes an approved label, and nothing here is a reason to start, stop or continue a prescribed medicine on your own. If you or someone you are caring for has a neuroendocrine neoplasm and is considering a GLP-1 or dual incretin agonist for diabetes or weight management, the tumor subtype, its receptor biology, and the reason the drug is being considered are all variables that belong in a conversation with the treating oncology and endocrinology team, not a decision made from an article. This article is for educational and journalistic purposes only and does not constitute medical advice. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.